Sat, Jan 24, 2015, 11:01 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

iShares China Large-Cap Message Board

koufax62 2 posts  |  Last Activity: Dec 17, 2014 7:35 PM Member since: Nov 16, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • koufax62 by koufax62 Dec 17, 2014 7:35 PM Flag

    Cash preserving personnel cuts to extend the on hand working capital runway thru P3 data & beyond into CY'16 on it's own looks like SOP, but combined with Nov positive P2 end point achieve plus auction of pre-clinic equipment has the feel of a bare bones reduction to just clinical pipeline/ongoing trials to be packaged to SD or other entity.

    Cut away all the non-essentials in prep for the large acquiring player closing the deal.

    IMO, the stock should have popped to 1.80-2.00 just on the recent data released in Nov + cash (Jan effect delayed reaction?) not including the SD partnership/asset so 300M+ in it's entirety appears well within the realm of reason.

    Any comments?

  • Reply to

    Rating By Fidelity and Conference Call

    by rgeorgekast Oct 30, 2014 11:30 AM
    koufax62 koufax62 Oct 31, 2014 12:35 AM Flag

    FWIW, I accumulated a position on the rising 200 (2.80) after a long absence from MT & Co until the debt overhang/street angst signaled a confirmed gradual dissipation via pay down & refi. Now net debt @79M (ttl debt less cash) and manageable with street focus now shifting primarily to value/potential of business segments & outlook incl patent port.

    A) Re; patents, excellent move monetizing IP via partnership with 3rd party patent enforcement entity eliminating go it alone litigation costs thus mitigating risks. Important Q answered right there for me.

    B) 3Q confirmed low point for gov't segment with return to growth ("traction") forecast for CY 15 via contracts of record (600M & 1B) anticipated funding.

    C) Cisco collaboration: a build out that incorporates all phases of TCS tech & expertise.

    D) Tom Brandt reiterating full year guidance for '14

    E) In-house 911 mandate imminent.

    No personal expectations for a 3Q beat for me. It's all about positioning for what I expect to be a strong CY '15

    Not as up to date as others here, but the valuation (@EV) is attractive and the outlook over the next 6-12 months appears vastly improved.

    I like it and will hold or add if low volume stupidity surfaces over the coming days.

    Koufax.

FXI
43.75-0.11(-0.25%)Jan 23 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Gran Tierra Energy, Inc.
AMEXFri, Jan 23, 2015 4:00 PM EST
Chemtura Corporation
NYSEFri, Jan 23, 2015 4:04 PM EST